Iron loading in HFE p.C282Y homozygotes found by population screening: relationships to HLA-type and T-lymphocyte subsets

Abstract

Iron loading in p.C282Y homozygous HFE hemochromatosis subjects is highly variable, and it is unclear what factors cause this variability. Finding such factors could aid in predicting which patients are at highest risk and require closest follow-up. The degree of iron loading has previously been associated with certain HLA-types and with abnormally low CD8 + cell counts in peripheral blood. In 183 Norwegian, p.C282Y homozygotes (104 men, 79 women) originally found through population screening we determined HLA type and measured total T-lymphocytes, CD4 + and CD8 + cells, and compared this with data on iron loading. In p.C282Y homozygous men, but not in homozygous women, we found that the presence of two HLA-A*03 alleles increased the iron load on average by approximately 2-fold compared to p.C282Y homozygous men carrying zero or one A*03 allele. On the other hand, the presence of two HLA-A*01 alleles, in male subjects, apparently reduced the iron loading. In p.C282Y homozygous individuals, the iron loading was increased if the CD8 + cell number was below the 25 percentile or if the CD4 + cell number was above the 75 percentile. This effect appeared to be additive to the effect of the number of HLA-A*03 alleles. Our data indicate that homozygosity for the HLA-A*03 allele significantly increases the risk of excessive iron loading in Norwegian p.C282Y homozygous male patients. In addition, low CD8 + cell number or high CD4 + cell number further increases the risk of excessive iron loading.

Keywords:

• Haplotypes
• HLA-A*03
• homozygote
• iron overload
• MHC

Acknowledgements

The precise work and dedication of Åslaug Heggli at the Hemochromatosis Clinic, Levanger Hospital during the collection, handling and transportation of all the samples is greatly acknowledged. The expert assistance with the HLA-typing provided by OK Storrø and M Aarhaug at the Department of Immunology and Transfusion Medicine, St. Olav Hospital, is highly appreciated.

Additional information

Funding

This study was supported by grants from the Norwegian University of Science and Technology, the Norwegian Haemochromatosis Association, and from Cederroth A/S.